Form 4: Xilio CMO's Stock Options Repriced, New Grant Issued

Xilio Therapeutics' Chief Medical Officer, Katarina Luptakova, saw several stock options repriced to $1.50 per share and received a new grant of 625,000 options.

Summary

• Katarina Luptakova, Chief Medical Officer of Xilio Therapeutics, Inc., had several existing stock options repriced.
• Effective November 21, 2025, the exercise price of these repriced options was reduced to $1.50 per share, unless exercised prior to November 21, 2026, in which case the original exercise price applies.
• Original exercise prices for the repriced options ranged from $2.37 to $9.69 per share.
• A new stock option grant of 625,000 shares was issued to Ms. Luptakova with an exercise price of $0.841 per share.
• This new grant was approved by the Board of Directors on October 8, 2025, and by stockholders on November 21, 2025, under the newly adopted Xilio Therapeutics, Inc. 2025 Stock Incentive Plan.
• The new 625,000 share options vest in 36 equal monthly installments over a three-year period, beginning on December 21, 2025, contingent on continued service.

Sentiment

Score: 4

Explanation: While the new grant and repricing re-incentivize a key executive, the underlying reason for the repricing (underwater options) points to significant past stock price decline, which is a negative signal for investors regarding past performance.

Positives

• Significant reduction in the exercise price for multiple existing stock options, making them more 'in-the-money' or closer to it, thereby restoring incentive value for the Chief Medical Officer.
• Grant of a substantial new stock option package (625,000 shares) at a low exercise price ($0.841), indicating continued commitment to incentivize the Chief Medical Officer.
• Stockholder approval of the 2025 Stock Incentive Plan provides a framework for future equity grants to attract and retain talent.

Negatives

• The necessity for an option repricing typically suggests that the company's stock price has fallen significantly below previous grant prices, indicating poor past stock performance.
• The repricing means that previous options were likely underwater, reducing their incentive value prior to this action.

Risks

• Potential for shareholder dilution from the new option grant and future exercises of both new and repriced options.
• The option repricing could be viewed negatively by some investors as it insulates management from poor stock performance at the expense of shareholders who may have purchased shares at higher prices.
• The company's stock price performance leading to the repricing indicates underlying business challenges or negative market sentiment.

Future Outlook

The adoption of the 2025 Stock Incentive Plan suggests the company intends to continue using equity compensation to incentivize employees and executives in the future. The new option grant to the Chief Medical Officer aligns her incentives with potential future stock price appreciation.

Industry Context

Option repricings are a mechanism often employed in the biotechnology sector, where stock prices can be highly volatile due to the inherent risks of drug development, clinical trials, and regulatory approvals. When a company's stock price significantly declines, previously granted options may become 'underwater,' losing their incentive value. Repricing aims to re-motivate key executives and retain talent by resetting option strike prices to current market levels, aligning their compensation with future performance from the new, lower base.

Comparison to Industry Standards

• While specific comparable companies are not named, option repricings are a known, albeit often controversial, practice in the biotechnology sector, particularly for companies experiencing significant stock price declines. The practice aims to restore the incentive value of equity awards for key personnel, a strategy also observed in other high-growth, high-risk industries where stock performance can be highly volatile.
• Corporate governance experts often view repricings with skepticism, as they can dilute shareholders and protect management from the consequences of poor stock performance. However, in highly competitive industries like biotech, the need to retain critical scientific and medical talent can sometimes outweigh these concerns, leading boards to approve such measures.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for dilution from the new option grant and future exercises of repriced options. The repricing itself may be viewed negatively as it protects executive incentives despite poor stock performance.
• Employees (specifically CMO): Increased incentive and retention due to the repricing of underwater options and the grant of new, lower-priced options.

Next Steps

• Continued vesting of the newly granted 625,000 stock options over 36 equal monthly installments beginning December 21, 2025.
• Continued vesting of other existing stock options according to their respective schedules.
• Potential future exercises of the repriced and newly granted options by the Chief Medical Officer.

Key Dates

Recommendation

While the repricing and new grant re-incentivize a key executive, the underlying reason for the repricing suggests significant past stock price underperformance. This indicates potential challenges for the company. Investors should hold and monitor future operational and financial results to assess if the re-incentivized management can drive a turnaround.

Keywords

Xilio Therapeutics, XLO, stock options, option repricing, executive compensation, insider transaction, Chief Medical Officer, Katarina Luptakova, 2025 Stock Incentive Plan